Finally, trials studying biologic therapies that prevent checkpoint inhibition (PD-1 inhibitors and PD-L1 inhibitors) and hormone therapy targeting somatostatin receptors with radioactive analogs also exhibit exciting potential as systemic pharmacotherapies for meningioma in the recurrent setting. This evidence concerns the gene CD274 and meningioma.